多种合并症与心力衰竭中指南指导的药物治疗强化的关联：EPIC-HF试验的结果
Association of multimorbidity with guideline-directed medical therapy intensification in heart failure: Findings from the EPIC-HF trial.
作者信息
Lipsey Jonathan, Allen Larry A, Page Robert L, Helmkamp Laura J, Venechuk Grace, Trinkley Katy E, Matlock Daniel D, McIlvennan Colleen K
机构信息
Division of Cardiology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Science, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
出版信息
Heliyon. 2024 Jul 5;10(13):e34178. doi: 10.1016/j.heliyon.2024.e34178. eCollection 2024 Jul 15.
A potential contributor to the suboptimal rates of guideline directed medical therapy (GDMT) prescribing for heart failure with reduced ejection fraction (HFrEF) is the burden of multimorbidity in patients with HFrEF. We examined the effect of multimorbidity on GDMT prescription in the EPIC-HF trial, finding that multimorbidity was associated with decreased likelihood of GDMT intensification. Further study is needed to guide treatment in high-risk, multimorbid patients with HFrEF.
射血分数降低的心力衰竭（HFrEF）患者中，指南指导的药物治疗（GDMT）处方率未达最佳水平的一个潜在因素是HFrEF患者的多种合并症负担。我们在EPIC-HF试验中研究了多种合并症对GDMT处方的影响，发现多种合并症与GDMT强化的可能性降低有关。需要进一步研究来指导高危、合并多种疾病的HFrEF患者的治疗。
Zotero 插件